

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



3.3.10 Systemic Immune-Mediated Diseases

Publications: 7 | Q1: 2

COMPOSITION

Juan José Ríos Blanco.

Coordinador Unidad EAS / FEA Medicina Interna. Hospital Universitario La Paz / IdiPAZ

- **Sergio Carrasco Molina.** FEA Medicina Interna. Hospital Universitario La Paz / FIBHULP
- **Belén del Pilar Gutiérrez Sancerni.** FEA Medicina Interna. Hospital Universitario La Paz
- **Ana María Noblejas Mozo.** FEA Medicina Interna. Hospital Universitario La Paz



STRATEGIC OBJETIVES

1. Establishment and consolidation of the group

- To create an efficient organizational structure for clinical research in systemic immune-mediated diseases
- Develop standardized protocols for clinical data collection
- Implement a unified database of patients with immune-mediated diseases

2. Development of clinical research excellence

- Design and conduct clinical trials in systemic immune-mediated diseases
- Establish collaborations with other national and international research groups
- Create prospective patient registries for observational studies

3. Implementation of translational research

- Establish a specific biobank for samples from patients with immune-mediated diseases
- Develop projects that connect clinical findings with basic research
- Identify biomarkers with potential clinical application

4. Development of innovative cell therapies

- Establish a cell therapy unit for immune-mediated diseases
- Develop personalized cell therapy protocols
- Implement clinical trials with advanced cell therapies

5. Training and education

- To train new researchers in the field of immune-mediated diseases
- Establish specific doctoral and master's programs
- Organize specialized seminars and workshops

RESEARCH LINES

1. Clinical and epidemiological characterization of systemic immune-mediated diseases

- Studies of natural history and prognostic factors
- Registration and monitoring of rare clinical manifestations
- Analysis of comorbidities and their therapeutic implications

2. Therapeutic optimization in immune-mediated diseases

- Studies of the effectiveness and safety of conventional and biological therapies
- Development of customized treatment algorithms
- Monitoring of adverse events and complications

3. Cell therapy in immune-mediated diseases

- Development of mesenchymal stem cell protocols
- CAR-T cell research for autoimmune diseases
- Studies of immune modulation using cell therapy

4. Biomarkers and personalized medicine

- Identification of prognostic and predictive biomarkers
- Development of specific activity and damage scores
- Implementation of precision medicine in clinical practice

5. Pathogenic mechanisms and new therapeutic targets

- Study of altered immunological pathways
- Identification of new therapeutic targets
- Clinical validation of basic findings

6. Research on patient-reported outcomes (PROs)

- Development and validation of specific questionnaires
- Quality of life and satisfaction studies
- Implementation of PROs in routine clinical practice



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



RESEARCH ACTIVITY

Doctoral Theses

- **Álvarez Troncoso J.** Prevalencia y factores de riesgo de cardiopatía e hipertensión pulmonar en pacientes con lupus eritematoso sistémico[dissertation]. Madrid: UAM: 2025(10/03/2025). Director: Ríos Blanco JJ.

Publications

- **Carrasco-Molina S, Robles-Marhuenda A, Ríos-Blanco JJ, Tung-Chen Y.** Counter-reply: comment to the special article [Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology. Rev Clin Esp. 2025; 225(7)]: 502337. Letter. IF: 1.7; Q2
- **Carrasco-Molina S, Robles-Marhuenda A, Ríos-Blanco JJ, Tung-Chen Y.** Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology. Rev Clin Esp. 2025; 225(4): 231-9. Article. IF: 1.7; Q2
- **Fuentes OP, Ballester LL, Troncoso JA, Abánades CIS, Mozo AN, Marhuenda AR, Blanco JJR, Sancerni BG, Rodríguez IE, Mora ET, Robles EM.** Inflammatory cerebral pseudotumour as a rare manifestation of neuro-Behçet's disease: A case report and literature review. J Neuroimmunol. 2025; 405: 578652. Review. IF: 3.1; Q3
- **Fuentes OP, Cepeda JG, Cabrera CV, de Bustamante JMM, Marhuenda AR, Troncoso JA, Robles EM, Mozo JAN, Blanco JJR, Fernández EG, Abánades CIS.** Renal involvement in primary Sjogren's syndrome: Beyond tubulointerstitial nephritis. Nefrologia. 2025; 45(7): 501341. Letter. IF: 2.1; Q3
- **Morales E, Rua-Figueroa I, Callejas Rubio JL, Ávila Bernabeu A, Blanco Alonso R, Cid Xutgla MC, Fernández Juárez G, Mena-Vázquez N, Ríos**

Blanco JJ, Manrique Escola J, Narváez García EJ, Sopena B, Quintana Porras LF, Romero-Yuste S, Solans Laque R. Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis. Nefrologia (Engl Ed). 2025; 45(1): 15-58. Review. Not Indexed

- **Morejón L, Quirce S, Domínguez-Ortega J, Romero D, Nobleja A, Ríos-Blanco J, De Las Vecillas L.** Mepolizumab as an effective alternative to immunosuppressive and teratogenic therapies for the early treatment of EGPA: A case report. J Invest Allerg Clin. 2025; 35(5): 389-91. Editorial Material. IF: 6.6; Q1
- **París-Muñoz A, Alcobendas-Rueda RM, Verdú-Sánchez C, Udaondo C, Galán-Gómez V, González-Martínez B, Menéndez JJ, Martínez-Romera I, Minguiellón J, Pertinex L, de Manuel-Gómez C, de la Cruz-benito A, Sanz-Rupérez A, Remesal A, Cámara C, Sánchez-Zapardiel E, del Pino-Molina L, Gómez-Zamora A, Serrano-Olmedo MG, Espanol-Rego M, Valbuena MRD, Climent F, Dorao P, Ríos-Blanco JJ, Andrade JD, Ruiz-Zurita G, Fernández-García MA, Pérez-Martínez A.** CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025; 6(8): 100676. Article. IF: 13.3; D1

Clinical trials

- **Ríos Blanco JJ.** A phase 1 open-label trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of subcutaneous vis171 in participants with autoimmune disease(s).

Type/Phase: I

Sponsored by: Visterra Inc.

Signature date: 18/06/2025